Coagulation and Fibrinolysis Activation Markers in Prostatic Carcinoma Patients

Clinical Chemistry and Laboratory Medicine

Volumn 35, Issue 2, 1997, Pages 69-72

  Geenen, Remy W F ^a   Delaere, Karl P J ^a   van Wersch, Jan W J ^a  

^a De Wever Hospital ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; PLASMIN; THROMBIN;

ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

ANTIFIBRINOLYTIC AGENTS; ANTIPLASMIN; ANTITHROMBIN III; BLOOD COAGULATION; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; MALE; PEPTIDE HYDROLASES; PLASMIN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030996670     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.1997.35.2.69     Document Type: Article

References (12)

1. Oliver A, Iglesias JM, Zuazu-Jausoro I, Parramon I, Laguna P, Fontcuberta J. Activation of coagulation and fibrinolysis in prostatic neoplasms [abstract], Thromb Haemostasis 1991; 65: 1054.
2. Adamson AS, Francis JL, Witherow RO, Snell ME. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance. Ann R Coll Surg Engl 1993; 75: 100-104.
3. Jurgens R, Trautwein H. Uber Fibrinopenie beim Erwachse-nen, nebst Bemerkungen uber die Herkunft des Fibrinogens. Dtsch Arch Klin Med 1930; 169: 28-43.
4. Buller HR, Boon TA, Henny CP, Dabhoiwala F, Ten Cate JW. Estrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer. J Urol 1982; 128: 72-74.
5. Uchiyama T, Matsumoto M, Kobayashi N. Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 1990; 59: 955-965.
6. Sagripanti A, Carpi A, Ferdeghini M, Baicchi U, Grassi B. Plasmatic markers of haemostatic system activation in patients with solid neoplasms. J Nucl Med Allied Sci 1990; 34: 321-332.
7. Nanninga PB, Van Teunenbroek A, Veenhof CHN, Buller HR, Ten Cate JW. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer. Thromb Haemostasis 1990; 64: 361-364.
8. Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H. Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio. Haemostasis 1992; 22: 179-186.
9. Hienert G, Kirchheimer JC, Pfliiger H, Binder BR. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 1988; 140: 1466-1469.
10. Roller A, Kirchheimer J, Pfliiger H, Binder BR. Tissue plasminogen activator activity in prostatic cancer. Eur Urol 1984; 10: 389-394.
11. Seitz R, Lerch L, Immel A, Egbring R. D-dimer tests detect both plasmin and neutrophil elastase derived split products. Ann Clin Biochem 1995; 32: 193-195.
12. Zacharski LR, Wojtukiewicz WZ, Constantini V, Omstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Sem Thromb Hemostasis 1992; 18: 104-116.